Sugi Predict

Sugi Predict / Compounds / SCHEMBL3486034

SCHEMBL3486034

SCHEMBL3486034

CCCC(C)OC(=O)CN

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FAAH O00519 5/20 0.42
▸ CNR1 P21554 1/20 0.42
▸ CNR2 P34972 1/20 0.42
▸ LMNA P02545 3/20 0.35
▸ CHRM1 P11229 2/20 0.34
▸ CHRM3 P20309 2/20 0.34
▸ AKR1A1 P14550 1/20 0.34
▸ HTR2A P28223 1/20 0.34
▸ HTR2C P28335 1/20 0.34
▸ ADRA1A P35348 1/20 0.34
▸ HRH1 P35367 1/20 0.34
▸ DRD3 P35462 1/20 0.34
▸ SLC6A3 Q01959 1/20 0.34
▸ HDAC1 Q13547 1/20 0.34
▸ HDAC2 Q92769 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ TSHR P16473 3/20 0.33
▸ METAP1 P53582 2/20 0.33
▸ CYP3A4 P08684 2/20 0.33
▸ NFKB1 P19838 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21023233 1.00 FAAH (0.42) FAAHCNR1CNR2LMNACHRM1
SCHEMBL19443244 1.00 FAAH (0.42) FAAHCNR1CNR2LMNACHRM1
SCHEMBL15427306 0.88 FAAH (0.51) FAAHCNR1CNR2LMNATDP1
SCHEMBL28633265 0.84 FAAH (0.61) FAAHCNR1CNR2LMNAMAPT
SCHEMBL14735548 0.84 FAAH (0.61) FAAHCNR1CNR2LMNAMAPT
SCHEMBL6670001 0.84 FAAH (0.61) FAAHCNR1CNR2LMNAMAPT
SCHEMBL28167554 0.84 FAAH (0.61) FAAHCNR1CNR2LMNAMAPT
SCHEMBL19787822 0.83 FAAH (0.39) FAAHCNR1CNR2LMNACHRM1
SCHEMBL15593349 0.82 — —
SCHEMBL905430 0.82 FAAH (0.53) FAAHCNR1CNR2LMNACHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3572410-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER Medivir Aktiebolag (SE) 2019-11-27 — — EP disclosed
US-9849191-B2 Protein-polymer-drug conjugates MERSANA THERAPEUTICS, INC. (US) 2017-12-26 — — US disclosed
US-20170348424-A1 PROTEIN-POLYMER-DRUG CONJUGATES MERSANA THERAPEUTICS, INC. 2017-12-07 — — US disclosed
EP-3252066-A1 HCV POLYMERASE INHIBITORS MEDIVIR AB (SE) 2017-12-06 — — EP disclosed
US-9808528-B2 Protein-polymer-drug conjugates and methods of using same MERSANA THERAPEUTICS, INC. (US) 2017-11-07 — — US disclosed
US-9770519-B2 Protein-polymer-drug conjugates MERSANA THERAPEUTICS, INC. (US) 2017-09-26 — — US disclosed
EP-3041855-B1 HCV POLYMERASE INHIBITORS MEDIVIR AB (SE) 2017-07-26 — — EP disclosed
US-20170119896-A1 TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF MERSANA THERAPEUTICS, INC. 2017-05-04 — — US disclosed
US-20160220696-A1 PROTEIN-POLYMER-DRUG CONJUGATES MERSANA THERAPEUTICS, INC. 2016-08-04 — — US disclosed
US-20160067353-A1 PROTEIN-POLYMER-DRUG CONJUGATES MERSANA THERAPEUTICS, INC. 2016-03-10 — — US disclosed
US-20140134127-A1 Protein-Polymer-Drug Conjugates MERSANA THERAPEUTICS, INC. (US) 2014-05-15 — — US disclosed
US-20140031523-A1 Selective Poly-N-Substituted Glycine Antibiotics BARRON ANNELISE E (US) 2014-01-30 — — US disclosed
US-20140017265-A1 Terminally Modified Polymers and Conjugates Thereof MERSANA THERAPEUTICS, INC. 2014-01-16 — — US disclosed
WO-2014008375-A1 TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF MERSANA THERAPEUTICS, INC. (US) 2014-01-09 — — WO disclosed
US-8445632-B2 Selective poly-N-substituted glycine antibiotics THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-05-21 — — US disclosed
US-20130101546-A1 Protein-Polymer-Drug Conjugates MERSANA THERAPEUTICS, INC. (US) 2013-04-25 — — US disclosed
US-20120295838-A1 Selective poly-substituted glycine antibiotics and related compositions BARRON ANNELISE E (US) 2012-11-22 — — US disclosed
EP-2252576-A2 SELECTIVE POLY-N-SUBSTITUTED GLYCINE ANTIBIOTICS Northwestern University (US) 2010-11-24 — — EP disclosed
US-20100036088-A1 Selective poly-N-substituted glycine antibiotics CHONGSIRIWATANA, NATHANIEL P. 2010-02-11 — — US disclosed
WO-2009105167-A2 SELECTIVE POLY-N-SUBSTITUTED GLYCINE ANTIBIOTICS NORTHWESTERN UNIVERSITY (US) 2009-08-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170348424-A1 PROTEIN-POLYMER-DRUG CONJUGATES PBRM1, CLTB, BRAP FAAH 3922/4885CNR1 2740/4885CNR2 3207/4885
US-20140134127-A1 Protein-Polymer-Drug Conjugates PBRM1, CLTB, BRAP FAAH 3922/4885CNR1 2740/4885CNR2 3207/4885
US-20100036088-A1 Selective poly-N-substituted glycine antibiotics PARG, PAM, NGLY1 FAAH 4685/4885CNR1 4572/4885CNR2 4465/4885
US-20140017265-A1 Terminally Modified Polymers and Conjugates Thereof MALT1, ALG1, PRMT3 FAAH 4461/4885CNR1 617/4885CNR2 1006/4885
US-20140031523-A1 Selective Poly-N-Substituted Glycine Antibiotics PARG, PAM, NGLY1 FAAH 4685/4885CNR1 4572/4885CNR2 4465/4885
US-20160067353-A1 PROTEIN-POLYMER-DRUG CONJUGATES PBRM1, CLTB, BRAP FAAH 3922/4885CNR1 2740/4885CNR2 3207/4885
US-20160220696-A1 PROTEIN-POLYMER-DRUG CONJUGATES PBRM1, PEBP1, STAMBP FAAH 3674/4885CNR1 3655/4885CNR2 3893/4885
US-20170119896-A1 TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF MALT1, ALG1, PRMT3 FAAH 4461/4885CNR1 617/4885CNR2 1006/4885
US-20130101546-A1 Protein-Polymer-Drug Conjugates PBRM1, CLTB, BRAP FAAH 3867/4885CNR1 2580/4885CNR2 3063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.